As far as I know, this is Roche's first brain shuttle molecule to enter clinical trials. Anyone else know of another? If true, then it is very surprising that Roche would start in Alzheimer's and with an amyloid beta approach. So many failures in testing the amyloid beta hypothesis. Could these past failures be overcome by increased brain penetration of the antibody?
Also noteworthy that MedImmune's two studies below concluded that the xB3/LRP1 approach outperformed the transferrin receptor antibody approach.